The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Catarina Craveiro, a biomedical research technician from Lisbon, had been hobbled by lower back pain from scoliosis since ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

SEVEN NEWS. HEY! WELCOME BACK. NEW PAIN MEDICATION HAS BEEN APPROVED BY THE FDA. IT SUPPOSEDLY NON-ADDICTIVE DARLENE MELENDEZ SPOKE WITH. UNM HEALTH EXPERT DOCTOR ASH ON HOW THIS WORKS.

A research team funded by the National Institutes of Health (NIH) has developed a medication that shows promise in treating acute and chronic pain.

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...

Researchers create a cannabis-derived compound that relieves pain without the risk of addiction or mind-altering effects.

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.